CIK 0001832038 · <br>Emerging growth company
Invivyd, Inc.
Sign in to watch- Ticker
- IVVD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851403134
- Phone
- (781) 819-0080
- Business address
- 205 CHURCH STREET, NEW HAVEN, CT
- Former names
- Adagio Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $177,089
- in 5 filings, $177K under 10b5-1 plans
Net −$177,089. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Andersen Jill −$53K Chief Legal Officer, Secretary sold 19% of stake
- Duke William E. −$32K Chief Financial Officer sold 19% of stake
- Green Julie −$32K Chief Human Resources Officer sold 19% of stake
- Lee Timothy Edward −$32K Chief Commercial Officer sold 19% of stake
- Allen Robert D. III −$29K Chief Scientific Officer sold 17% of stake
Reading 22 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-15 | Allen Robert D. III Chief Scientific Officer | Option exercise 10b5-1 | +102,000 | 216,487 | ||
| 2026-08-15 | Allen Robert D. III Chief Scientific Officer | Option exercise · Restricted Stock Units 10b5-1 | −102,000 | 0 | ||
| 2026-07-31 | Mina Michael CMO and Chief Epidemiologist | Grant or award · Stock Option (Right to Buy) | +1,125,000 | 1,125,000 | ||
| 2026-05-19 | Royan Ajay Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-05-19 | MCLAUGHLIN KEVIN F Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-05-19 | MCGUIRE TERRANCE Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-05-19 | Elia Marc Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-05-19 | BOLNO PAUL Director | Grant or award · Stock Option (Right to Buy) | +32,876 | 32,876 | ||
| 2026-05-19 | Berry Tamsin Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-02-18 | Allen Robert D. III Chief Scientific Officer | Sale 10b5-1 | −19,392 | $1.58 | $31K | 114,487 |
| 2026-02-18 | Green Julie Chief Human Resources Officer | Sale 10b5-1 | −20,964 | $1.58 | $33K | 107,717 |
| 2026-02-18 | Duke William E. Chief Financial Officer | Sale 10b5-1 | −20,964 | $1.58 | $33K | 107,717 |
| 2026-02-18 | Lee Timothy Edward Chief Commercial Officer | Sale 10b5-1 | −20,964 | $1.58 | $33K | 117,717 |
| 2026-02-18 | Andersen Jill Chief Legal Officer, Secretary | Sale 10b5-1 | −34,939 | $1.58 | $55K | 181,736 |
| 2026-02-17 | Allen Robert D. III Chief Scientific Officer | Sale 10b5-1 | −18,189 | $1.54 | $28K | 133,879 |
| 2026-02-17 | Green Julie Chief Human Resources Officer | Sale 10b5-1 | −19,663 | $1.54 | $30K | 128,681 |
| 2026-02-17 | Duke William E. Chief Financial Officer | Sale 10b5-1 | −19,663 | $1.54 | $30K | 128,681 |
| 2026-02-17 | Lee Timothy Edward Chief Commercial Officer | Sale 10b5-1 | −19,663 | $1.54 | $30K | 138,681 |
| 2026-02-17 | Andersen Jill Chief Legal Officer, Secretary | Sale 10b5-1 | −32,771 | $1.54 | $50K | 216,675 |
| 2026-02-15 | Allen Robert D. III Chief Scientific Officer | Option exercise 10b5-1 | +99,000 | 152,068 |
Page 2 of 9 · 161 trades